Literature DB >> 18519514

Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia.

Anne Ricksten, Lars Palmqvist, Peter Johansson, Björn Andreasson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18519514     DOI： 10.3324/haematol.12801

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

Review 1.  Do we know more about essential thrombocythemia because of JAK2V617F?

Authors:  Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

2.  Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.

Authors:  Elisabetta Antonioli; Alessandra Carobbio; Lisa Pieri; Alessandro Pancrazzi; Paola Guglielmelli; Federica Delaini; Vanessa Ponziani; Niccolò Bartalucci; Lorenzo Tozzi; Alberto Bosi; Alessandro Rambaldi; Tiziano Barbui; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2010-04-23       Impact factor: 9.941

3.  Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study.

Authors:  François Girodon; Gilles Bonicelli; Céline Schaeffer; Morgane Mounier; Serge Carillo; Ingrid Lafon; Paule Marie Carli; Inès Janoray; Emmanuelle Ferrant; Marc Maynadié
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

4.  Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.

Authors:  Eric Lippert; François Girodon; Emma Hammond; Jaroslav Jelinek; N Scott Reading; Boris Fehse; Katy Hanlon; Mirjam Hermans; Céline Richard; Sabina Swierczek; Valérie Ugo; Serge Carillo; Véronique Harrivel; Christophe Marzac; Daniela Pietra; Marta Sobas; Morgane Mounier; Marina Migeon; Sian Ellard; Nicolaus Kröger; Richard Herrmann; Josef T Prchal; Radek C Skoda; Sylvie Hermouet
Journal:  Haematologica       Date:  2008-11-10       Impact factor: 9.941

5.  Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden.

Authors:  Ilana Renault Zalcberg; Jackline Ayres-Silva; Alexandre Mello de Azevedo; Cristiana Solza; Adelmo Daumas; Martin Bonamino
Journal:  Haematologica       Date:  2011-03       Impact factor: 9.941

6.  JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.

Authors:  Alessandro M Vannucchi; Lisa Pieri; Paola Guglielmelli
Journal:  Ther Adv Hematol       Date:  2011-02

7.  Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Authors:  Emil Kuriakose; Katherine Vandris; Y Lynn Wang; William Chow; Amy V Jones; Paul Christos; Nicholas C P Cross; Richard T Silver
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

8.  Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.

Authors:  Shuichi Shirane; Marito Araki; Soji Morishita; Yoko Edahiro; Yoshitaka Sunami; Yumi Hironaka; Masaaki Noguchi; Michiaki Koike; Eriko Sato; Akimichi Ohsaka; Norio Komatsu
Journal:  Int J Hematol       Date:  2014-12-19       Impact factor: 2.490

9.  High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio.

Authors:  Magnus Tobiasson; Bassam Alyass; Susanne Söderlund; Gunnar Birgegård
Journal:  Med Oncol       Date:  2009-02-19       Impact factor: 3.064

10.  Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia.

Authors:  Anna L Godfrey; Edwin Chen; Francesca Pagano; Yvonne Silber; Peter J Campbell; Anthony R Green
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.